The first clinical studies combining radiotherapy with ipilimumab (anti-CTLA-4-antibody; cytotoxic T-lymphocyte-associated protein 4) against prostate cancer and case reports in melanoma underline the significance of this clinical approach [102,103,104,105]. This evidence concerns the gene CTLA4 and prostate cancer.